JOHN L. FAHEY, M.D.
This content is PDF only. Please click on the PDF icon to access.
Manipulation of normal body processes to achieve therapeutic benefit may lead to undesired and late appearing complications. This seems to be the case with induced immune suppression, where cancer develops as a late complication in some patients. Neoplastic disease in immunosuppressed patients is now documented at an incidence far higher (100 times greater) than would be expected in the general population. The clinical evidence is supported by observations in experimental animals. These findings point to the need to consider the possibility of this undesirable side effect before undertaking administration of drugs that may be immunosuppressive, as well as the need
FAHEY JL. Cancer in the Immunosuppressed Patient. Ann Intern Med. 1971;75:310–312. doi: https://doi.org/10.7326/0003-4819-75-2-310
Download citation file:
Published: Ann Intern Med. 1971;75(2):310-312.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use